Company Monitoring Page for Biogen

latest headlines for company on cafepharma

JPM21: Biogen faces make-or-break year, Vertex mulls deals and Sarepta pitches a silver lining
BioPharma Dive
Mon, 01/11/21 - 07:06 pm
Tags:
JPMHC 2021, Biogen, Vertex Pharmaceuticals, Sarepta Therapeutics
Biogen, Genentech and F-Prime power new neurodegenerative biotech to $110M unveiling
Fierce Biotech
Mon, 01/11/21 - 10:30 am
Tags:
Atalanta Therapeutics, Biogen, Genentech, F-Prime, neurodegenerative disease
10 Biopharma Stories to Look Forward to in 2021
BioSpace
Sun, 01/3/21 - 04:39 pm
Tags:
pandemic, COVID-19, vaccines, Joe Biden, drug pricing, M&A, venture capital, JNJ, Biomarin, Bluebird Bio, TG Therapeutics, Biogen, AstraZeneca
3 FDA Dates Biotech Investors Should Circle in 2021
Motley Fool
Sat, 12/26/20 - 08:27 pm
Tags:
FDA, biotech, Bluebird Bio, ide-cel, Multiple Myeloma, Biogen, aducanumab, Alzheimer's disease, targeted therapeutics, umbralisib, maringal zone lymphoma
2021 Best Places to Work in Medical Sales
MedReps.com
Tue, 12/22/20 - 10:58 am
Tags:
devices, drug reps, Syneos Health, Teleflex, Avion Pharmaceuticals, Acella, Conmed, Acumed, Lundbeck, Amgen, Biogen, Spark Therapeutics
Biogen to pay $22 million to resolve U.S. drug charity kickback probe
Reuters
Thu, 12/17/20 - 06:30 pm
Tags:
Biogen, MS, kickbacks, Medicare, multiple sclerosis
Biogen Corporate Event Was COVID Superspreader, Up to 300,000 Related Infections, Study Says
BioSpace
Fri, 12/11/20 - 11:15 am
Tags:
Biogen, COVID-19, pandemic, superspreaders, conferences
Public Citizen Demands Investigation into "Inappropriate Collaboration" Between FDA and Biogen Over Alzheimer's Drug
BioSpace
Wed, 12/9/20 - 10:59 pm
Tags:
Biogen, OIG, HHS, aducanumab, Public Citizen, Alzheimer's disease
Is Biogen Getting Desperate?
Motley Fool
Wed, 12/9/20 - 10:42 am
Tags:
Biogen, SAGE Therapeutics, major depressive disorder, depression
[video+transcript]Here's Why Biotech Deals Are All the Rage Right Now
Motley Fool
Sat, 12/5/20 - 11:24 pm
Tags:
biotech, M&A, Biogen, SAGE Therapeutics, Eli Lilly, Precision Biosciences, Merck, OncoImmune
Biogen bets $1.5B on Sage's once-failed depression drug
Fierce Biotech
Mon, 11/30/20 - 10:29 am
Tags:
Biogen, SAGE Therapeutics, zuranolone, depression
Biogen stocks up on Sage's brain drugs in $3B deal
BioPharma Dive
Fri, 11/27/20 - 04:49 pm
Tags:
Biogen, SAGE Therapeutics, brain diseases
FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar
Pharmaforum
Thu, 11/19/20 - 10:33 am
Tags:
Novartis, Genentech, Lucentis, biosimilars, Samsung Bioepis, Biogen, FDA
Biogen's Possible Shopping List: 3 Companies the Biotech Might Buy
Motley Fool
Wed, 11/11/20 - 11:01 am
Tags:
Biogen, M&A, Aurinia, Cassava Sciences, Heron Therapeutics
Biogen ‘continues to work’ with FDA on Alzheimer's drug candidate despite regulatory setback
Biopharma Reporter
Tue, 11/10/20 - 10:36 am
Tags:
Biogen, FDA, Alzheimer's disease, aducanumab
5 takeaways from the FDA's high-stakes meeting for Biogen's Alzheimer's drug
BioPharma Dive
Mon, 11/9/20 - 08:56 pm
Tags:
Biogen, FDA, Alzheimer's disease, aducanumab, clinical trials, amyloid
Why Biogen Stock Is Tanking Today
Motley Fool
Mon, 11/9/20 - 11:02 am
Tags:
Biogen, aducanumab, FDA, Alzheimer's disease
FDA advisers vote against Biogen's Alzheimer's drug, leaving its future in doubt
Biopharma Dive
Fri, 11/6/20 - 08:46 pm
Tags:
Biogen, aducanumab, FDA, advisory panels, Alzheimer's disease
The FDA's insider review on aducanumab was all about politics, not science, and it threatens patients and the biopharma industry alike
Endpoints
Fri, 11/6/20 - 10:19 am
Tags:
FDA, Biogen, aducanumab, Alzheimer's disease
FDA scientists appear to offer major endorsement of Biogen’s controversial Alzheimer’s treatment
Stat
Wed, 11/4/20 - 10:50 am
Tags:
Biogen, aducanumab, Alzheimer's disease, FDA, advisory panels

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.